At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
bevacizumab [Avastin] +1 moredrug
Likely dose
bevacizumab [Avastin] 7.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy
In Brief
A Phase 2 clinical trial evaluating bevacizumab [Avastin] and capecitabine [Xeloda] for Liver Cancer. Completed, enrolled 45 participants across 7 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy and safety of oral Xeloda (capecitabine) plus intravenous Avastin (bevacizumab) in patients with advanced or metastatic liver cancer. The anticipated time on study treatment is 3-12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesAustralia, Hong Kong, Singapore, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
Primary CompletionMar 2008
First PostedDec 2013
TodayJul 2026
First PostedDec 17, 2013
Enrollment StartMay 1, 2005
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.5 years ago
Interventions
bevacizumab [Avastin]drug
7.5mg/kg iv on day 1 of each 3 week cycle.
capecitabine [Xeloda]drug
1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.